Intellia Therapeutics Inc.

Hereditary Angioedema

Clinical research includes hereditary angioedema, with studies focused on hereditary angioedema due to C1 esterase inhibitor deficiency and related attack prevention. The programme also includes long-term follow-up in treated participants and evaluation of disease control in adults with recurrent swelling episodes.

  • HAE attacks
  • C1 esterase inhibitor deficiency
  • Long-term safety

Research activity in this area is centred on reducing disease burden in patients with recurrent angioedema episodes.

Transthyretin Amyloidosis

The sponsor supports trials in transthyretin amyloidosis, including both hereditary transthyretin amyloidosis with polyneuropathy and transthyretin amyloidosis-related cardiomyopathy. These studies address neurological and cardiac manifestations of the disease, with follow-up in previously treated participants.

  • ATTRv-PN
  • ATTR-CM
  • Cardiac muscle disease

Work in this field reflects a strong focus on inherited amyloid disorders affecting the peripheral nerves and the heart.

Alpha-1 Antitrypsin Deficiency

Clinical investigation also extends to alpha-1 antitrypsin deficiency-associated lung disease, including pulmonary emphysema. The research programme examines lung-related disease in adults with inherited deficiency states and associated respiratory impairment.

  • AATD-associated lung disease
  • Pulmonary emphysema
  • Adult respiratory disease

This area adds a pulmonary dimension to the sponsor’s portfolio of inherited disease research.

Genetic Medicine

The overall portfolio is concentrated in genetic medicine and rare disease research, with activity across inherited disorders that affect the immune, neurological, cardiac, and respiratory systems. The sponsor’s clinical work spans multiple countries and research sites, supporting studies in severe monogenic conditions.

  • Rare inherited disorders
  • Neurological disease
  • Cardiovascular disease

Medical affairs activity is directed toward clinical development in genetically defined patient populations.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Long-Term Safety Study of NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy or Transthyretin Amyloidosis-Related Cardiomyopathy

    Recruiting

    1 1 1
    Investigated drugs:
    France Sweden
  • Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands
  • Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

    Not yet recruiting

    1 1 1
    Austria Belgium Czechia Denmark France Germany +8
  • Study on NTLA-2002 for Treating Hereditary Angioedema in Patients: Evaluating the Effects of Ziclumeran and Lonvoguran

    Not recruiting

    1 1 1
    Investigated diseases:
    France Germany The Netherlands
  • Study on NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy

    Not recruiting

    1 1
    Investigated drugs:
    France Sweden
  • Study on the Safety of NTLA-3001 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung Disease

    Not recruiting

    1 1
    Investigated drugs:
    Ireland